141 related articles for article (PubMed ID: 27583543)
1. Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis.
Montgomery SA; Lyndon G; Almas M; Whalen E; Prieto R
Int Clin Psychopharmacol; 2017 Jan; 32(1):41-48. PubMed ID: 27583543
[TBL] [Abstract][Full Text] [Related]
2. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.
Lydiard RB; Rickels K; Herman B; Feltner DE
Int J Neuropsychopharmacol; 2010 Mar; 13(2):229-41. PubMed ID: 19737439
[TBL] [Abstract][Full Text] [Related]
4. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials.
Bech P
Pharmacopsychiatry; 2007 Jul; 40(4):163-8. PubMed ID: 17694480
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing.
Pohl RB; Feltner DE; Fieve RR; Pande AC
J Clin Psychopharmacol; 2005 Apr; 25(2):151-8. PubMed ID: 15738746
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
Merideth C; Cutler AJ; She F; Eriksson H
Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
Feltner DE; Crockatt JG; Dubovsky SJ; Cohn CK; Shrivastava RK; Targum SD; Liu-Dumaw M; Carter CM; Pande AC
J Clin Psychopharmacol; 2003 Jun; 23(3):240-9. PubMed ID: 12826986
[TBL] [Abstract][Full Text] [Related]
9. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
10. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis.
Stein DJ; Bruce Lydiard R; Herman BK; Mandel FS
Int Clin Psychopharmacol; 2009 May; 24(3):126-32. PubMed ID: 19352198
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
[TBL] [Abstract][Full Text] [Related]
12. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin versus sertraline in generalized anxiety disorder. An open label study.
Cvjetkovic-Bosnjak M; Soldatovic-Stajic B; Babovic SS; Boskovic K; Jovicevic M
Eur Rev Med Pharmacol Sci; 2015; 19(11):2120-4. PubMed ID: 26125277
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability.
Montgomery S; Emir B; Haswell H; Prieto R
Curr Med Res Opin; 2013 Oct; 29(10):1223-30. PubMed ID: 23808960
[TBL] [Abstract][Full Text] [Related]
15. Pregabalin for the treatment of generalized anxiety disorder.
Wensel TM; Powe KW; Cates ME
Ann Pharmacother; 2012 Mar; 46(3):424-9. PubMed ID: 22395254
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
Feltner DE; Liu-Dumaw M; Schweizer E; Bielski R
Int Clin Psychopharmacol; 2011 Jul; 26(4):213-20. PubMed ID: 21368587
[TBL] [Abstract][Full Text] [Related]
17. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice.
Ruiz MA; Álvarez E; Carrasco JL; Olivares JM; Pérez M; Rejas J
Drug Des Devel Ther; 2015; 9():4329-40. PubMed ID: 26273194
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of pregabalin in generalized anxiety disorder.
Feltner D; Wittchen HU; Kavoussi R; Brock J; Baldinetti F; Pande AC
Int Clin Psychopharmacol; 2008 Jan; 23(1):18-28. PubMed ID: 18090504
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder.
Montgomery S; Chatamra K; Pauer L; Whalen E; Baldinetti F
Br J Psychiatry; 2008 Nov; 193(5):389-94. PubMed ID: 18978320
[TBL] [Abstract][Full Text] [Related]
20. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
Pollack MH; Tiller J; Xie F; Trivedi MH
J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
